Clinical Assessment of the Effectiveness and Safety of Herpes Patch SOS in the Treatment of Herpes Simplex Labialis in Comparison to a Competitor's Product.

Technische Universität Dresden

Status: Completed

Conditions: Herpes Simplex Labialis

Treatments: Other: Herpes Patch SOS (Hansaplast®); Other: Herpes vesicle patch of Compeed®

Study type: Interventional

Funder types: Other

Identifiers

NCT02157090

Herpes patch study 32583

Details and patient eligibility

About

Recent clinical studies showed, that a hydrocolloid patch is effective, well tolerated and comparable with aciclovir cream 5 % for the treatment of HSL lesions, while affording additional benefits of wound protection, discretion and relief of social embarrassment. The aim of the actual study was the clinical assessment of the effectiveness and safety of Hansaplast® SOS Herpes Patch (HPHP) in comparison to Compeed® Herpes Vesicle Patch (CHP) in treating HSL. Both products are CE-certificated and are available at the market for medical devices.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• at least 18 years old
• with a history of recurrent HSL of the lips and/or perioral skin
• lesions typically manifesting as classical lesions
• duration of HSL symptoms not more than three days
• haven´t used acyclovir or other cold sore therapies

Exclusion criteria

• pregnancy
• lactating women
• women of child-bearing age without medically secured contraceptions
• topical or systemic therapy with analgesic
• anti-inflammatory or antiviral agents within the last 2 weeks
• topical therapy within the treatment area
• systemic therapy with cytostatics or immunosuppressants

Trial design

0 participants in 2 patient groups

Herpes Patch SOS (Hansaplast®)

Active Comparator group

Treatment:

Other: Herpes Patch SOS (Hansaplast®)

Herpes vesicle patch of Compeed®

Active Comparator group

Treatment:

Other: Herpes vesicle patch of Compeed®